ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

AbbVie ABBV stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks ...

AbbVie ABBV generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake ...

Detailed price information for Taiwan Semiconductor ADR (TSM-N) from The Globe and Mail including charting and trades.

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate ...